Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$40.62 - $79.62
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.27M
Market Cap
$9.19B
Enterprise Value$14.35B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 07, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding185,076,300
10 Day Avg. Volume1,965,092
30 Day Avg. Volume2,268,953
Standard Deviation0.16
R-Squared0.17
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.41
Price to Cash Flow (P/CF)16.60
P/FCF Ratio29.70
Enterprise Value/Market Cap1.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.77
Enterprise Value/Ebitda546.06
Forecast
1Y Price Target
$72.67Price Target Upside43.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
EarningsScreening revenues beat expectations, growing 13.5% and 3% above analysts and market consensus.
Pricing StrategyEXAS secures a price increase of approximately $592 per test for Cologuard Plus, representing a 16% rise compared to its first generation Cologuard test.
Product LaunchEXAS plans to launch Cologuard Plus, Oncodetect (MRD), and Cancerguard (multi-cancer screening test).
Bears Say
Sales Force ChallengesThe screening segment has suffered due to sales force challenges, such as insufficient follow-up between sales and new prescribers, misaligned incentives, and poor division of sales territories.
Sales ShortfallResults were driven by Cologuard strength after 3Q’s shortfall.
Transition UncertaintyEXAS had previously indicated the timing could look like ~12-24 months to make the full transition, suggesting a strategic planning process for future price increases.
---
Ownership Overview
1.02% Insiders
47.03% Mutual Funds
34.24% Other Institutional Investors
2.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $40.62 and its highest was $79.62 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $9.19B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is May 07, 2025 which is in 75 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Feb 19, 2025. The company reported -$4.67 earnings per share for the quarter, missing the consensus estimate of -$0.307 by -$4.363.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.33.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 185,076,300 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$4.67 in its last earnings report, missing expectations of -$0.307. Following the earnings report the stock price went down -1.922%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
---
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.67 (43.96% Upside)
$72.67 (43.96% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 113.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.20%
12-Months-Change
Fundamentals
Return on Equity
-42.83%
Trailing 12-Months
Asset Growth
5.10%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXAS Company Deck
---
EXAS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance with significant revenue and EBITDA growth, especially in the Screening segment. The company highlighted major achievements like FDA approval for Cologuard Plus and strong international expansion in Precision Oncology. However, the call also addressed challenges such as a substantial non-cash impairment charge related to the Thrive acquisition and modest growth in Precision Oncology. Overall, the positive aspects of revenue growth, new product launches, and strategic advancements outweigh the lowlights, indicating a positive sentiment.Read More>---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Month Forecast
Average Price Target
$72.67
▲(43.96% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+32.96%
reiterated a buy rating 5 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +32.96% per trade.
---